L’outil de licence Creative Commons du formulaire de soumission ne fonctionne pas actuellement. Pour ajouter une licence CC à votre thèse ou publication, contactez ruor@uottawa.ca après le dépôt. -- The Creative Commons licence tool in the submission form is currently unavailable. To apply a CC licence to your thesis or publication, contact ruor@uottawa.ca after the deposit.

The Role of PARylation in Inflammatory Mediated Subclass of Preeclampsia

En cours de chargement...
Vignette d'image

Nom de la revue

ISSN de la revue

Titre du volume

Éditeur

Université d'Ottawa | University of Ottawa

Résumé

Preeclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality, diagnosed after 20 weeks of gestation. Several subclasses of PE have been identified, each with distinct pathophysiology. Notably, the inflammation-mediated subclass (I-PE) is characterized by a pronounced increase in placental PARylation and a marked depletion of NAD+. This study investigates the mechanistic basis of this phenotype by profiling placental NAD+ -consuming enzymes and assessing whether selective inhibition of PARylating enzymes can restore trophoblast function and placenta health. HTR-8/SVneo trophoblast cells were exposed to TNF-α to mimic the I-PE inflammatory environment in vitro. Cells were also co-treated with Olaparib (a PARP1/2 inhibitor) or XAV939 (a PARP5a/5b inhibitor), as PARP1/2 and PARP5a/5b have been identified as key PARylating enzymes in the placenta. Total protein PARylation, cellular viability, mitochondrial func-on, and migratory capacity were assessed as cellular health and functional outcomes. TNF-α exposure increased total protein PARylation and impaired mitochondrial health by decreasing oxygen consumption rates during respiration, cellular viability and migration. Co- treatment with Olaparib reduced protein PARylation within 1h and restored cellular viability and migration, and mitochondrial respiration despite the continued pro-inflammatory conditions. In contrast, co-treatment with XAV939 showed no improvement in cellular health or function. These findings suggest that inflammation-induced PARP1/2 activation may contribute to placental PARylation and NAD+ depletion in I-PE and highlight the PARP1/2- NAD+ axis as a potential therapeutic target to improve placental health and func-on in affected pregnancies.

Description

Mots-clés

Metabolism, Placenta, Trophoblast, HTR-8, PARP, Inflammation, TNF-a, SIRT, Seahorse, 4HNE, OXPHOS, Preeclampsia, Oxidative stress, NAD, Olaparib

Citation

Approbation

Évaluation

Complété par

Référencé par